|
gptkbp:instanceOf
|
antidepressant
heterocyclic compound
|
|
gptkbp:approvalYear
|
1992
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
N06AA17
|
|
gptkbp:brand
|
gptkb:Amoxan
gptkb:Asendin
gptkb:Demitasse
|
|
gptkbp:CASNumber
|
14028-44-5
|
|
gptkbp:contraindication
|
seizure disorders
recent myocardial infarction
concurrent MAOI use
|
|
gptkbp:discoveredBy
|
gptkb:Wyeth
|
|
gptkbp:eliminationHalfLife
|
8-30 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
VZJYTIWCBZQZJH-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C17H16ClN3O
|
|
gptkbp:hasSMILES
|
Clc1ccc2c(c1)N(c3ccccc3C2)CN4CCOCC4
|
|
gptkbp:hasUNII
|
U4VPS3565Z
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Amoxapine
|
|
gptkbp:IUPACName
|
8-chloro-6-(4-morpholinyl)-11H-dibenz[b,e]azepine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
dopamine receptor antagonist
|
|
gptkbp:metabolism
|
gptkb:loxapine
liver
|
|
gptkbp:molecularWeight
|
313.78 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
90%
|
|
gptkbp:PubChem_CID
|
2161
DB00543
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
constipation
weight gain
seizures
drowsiness
dry mouth
tardive dyskinesia
|
|
gptkbp:usedFor
|
gptkb:depression
gptkb:major_depressive_disorder
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|